Last reviewed · How we verify

Xenleta — Competitive Intelligence Brief

Xenleta (LEFAMULIN) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pleuromutilin Antibacterial. Area: Infectious Disease.

marketed Pleuromutilin Antibacterial Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Xenleta (LEFAMULIN) — Hong Kong.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xenleta TARGET LEFAMULIN Hong Kong marketed Pleuromutilin Antibacterial 2019-01-01
Altabax RETAPAMULIN Almirall marketed Pleuromutilin Antibacterial 2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pleuromutilin Antibacterial class)

  1. Almirall · 1 drug in this class
  2. Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xenleta — Competitive Intelligence Brief. https://druglandscape.com/ci/lefamulin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: